Sudarshan Pharma Industries Ltd Growth Catalysts - SOIC x StockScans Report
as of Jul 2026
- FCCB fundraise - USD 20 million - The Board allotted the first USD 10 million of 8% senior unsecured FCCBs due 2029 on 21 May 2026, with an option to raise a further USD 10 million within 60 days. The ₹192 crore equivalent inflow funds the company's growth pipeline at a time when debt is already ₹283 crore, directly strengthening the balance sheet for near-term capex and working-capital needs.
- Srigen API facility acquisition - Hyderabad - A definitive agreement was signed to acquire a fully operational, GMP-compliant Hyderabad API facility with 80-kilolitre reactor capacity for ₹25.5 crore, with completion targeted by 31 December 2025. The plant adds instant, multi-product manufacturing capacity for high-value molecules such as Sitagliptin, Apixaban and Rivaroxaban, removing the lead time and regulatory risk of a greenfield build.
- Ratna Lifesciences oncology ramp-up - The wholly owned oncology subsidiary grew revenue from ₹9.22 crore in FY25 to ₹35.30 crore in FY26 and is acquiring adjacent MIDC land to multiply plant capacity roughly tenfold. Oncology APIs carry structurally higher margins than the company’s legacy trading and generics mix, so this trajectory directly expands the group’s blended profitability.
- Export scale-up - ₹100 crore target for FY27 - Management targets a minimum export turnover of ₹100 crore in FY27, up from ₹21.85 crore in FY26, by adding regulated-market registrations and expanding the high-value API range. Hitting that target would lift exports from roughly 3% to over 10% of revenue, improving both geographic diversification and realisations.
- PLI Vitamin B1 and B6 greenfield projects - Gujarat - The Department of Pharmaceuticals approved a location shift to GIDC, Gujarat, with a revised commercial operation date of 31 December 2027 for both vitamin projects. When commissioned, backward-integrated vitamin manufacturing under the PLI scheme adds a protected, incentive-backed earnings stream in a product category India currently imports heavily.
- Preferential warrant issue - ₹188 crore - The company proposes to raise ₹188.34 crore by issuing 4.30 crore fully convertible warrants to promoter and non-promoter investors at ₹43.80 per warrant, pending BSE in-principle approval. The equity infusion, alongside the FCCB proceeds, materially deleverages the D/E of 1.83x and funds the next leg of asset creation.
- Main-board migration - BSE and NSE - The Board approved migration from the BSE SME platform to the BSE Main Board and an application for NSE listing on 21 May 2026, subject to shareholder approval. A main-board listing widens the institutional investor base and can improve trading liquidity and valuation multiples for a ₹920-crore market-cap company.
- Palghar Unit 2 oral liquids - capacity online - Unit 2 in Palghar is operational with a 1,000-litre tank producing 2,000 litres per shift, scalable to 6,000 litres across two shifts, and holds approvals for 50 products for domestic and international markets. The unit adds a finished-formulations revenue stream that captures margin otherwise left with third-party manufacturers.